Cellectar Biosciences, Inc.
CLRB · XNASCIK 1279704fmd_14DA51B3FT8B22VFCM8TP8850RManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2003 to Sep 30, 2026, 73 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | 5 | 9 | 7 | 9 | 10 | 18 | 18 | 27 | 26 | 11 |
| Operating income | (9) | (14) | (13) | (14) | (15) | (24) | (29) | (39) | (52) | (23) |
| Other non-operating income (expense) | 3 | 0 | 0 | 0 | 0 | 0 | (3) | (4) | 7 | 1 |
| Income before taxes | – | – | – | – | – | (24) | (32) | (43) | (45) | (22) |
| Income tax expense | 0 | 0 | 0 | 0 | – | – | (0) | (0) | 0 | – |
| Net income from continuing operations | – | – | – | – | – | – | (32) | (43) | (45) | – |
| Net income | (6) | (14) | (13) | (14) | (15) | (24) | (32) | (43) | (45) | (22) |
| Net income to common shareholders | (9) | (15) | (15) | (14) | – | – | – | – | – | – |